Melanoma

According to the American Cancer Society, melanoma accounts for 1% of all skin cancers.

Rates of melanoma have been rising for the last 30 years, with the lifetime risk for melanoma being about 1 in 40 for caucasians. 

GoPath has developed several molecular tests to diagnose melanoma and to detect biomarkers or genes that may influence treatment decisions. This means that our tests yield results that help your doctor create a treatment plan that is tailor-made for your particular type of cancer. 

These tests include:

          •     Melanoma Profile - Examines genes such as BRAF, NRAS, cKIT and PDL1 (IHC)
          •     OncoTargetTM - Detects genetic mutations in a cancer to monitor treatment resistance
          •     Skin Biopsy